Optimized Antibodies that Target CD19
First Claim
Patent Images
1. An antibody that binds CD19, said antibody comprising a heavy chain and/or a light chain, said heavy chain having a CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 132 and 138, a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;
111-115 and a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;
116-118; and
said light chain having a CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;
119-128, a CDR2 comprising the amino acid sequence of SEQ ID NOs;
129, and a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;
130-131.
1 Assignment
0 Petitions
Accused Products
Abstract
Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.
117 Citations
25 Claims
-
1. An antibody that binds CD19, said antibody comprising a heavy chain and/or a light chain, said heavy chain having a CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 132 and 138, a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;
111-115 and a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;
116-118; and
said light chain having a CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;
119-128, a CDR2 comprising the amino acid sequence of SEQ ID NOs;
129, and a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;
130-131. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25)
- 132 and 138, a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;
-
18. A composition comprising plurality of glycosylated antibodies, wherein about 80-100% of the glycosylated antibody in the composition comprises a mature core carbohydrate structure which lacks fucose.
Specification